Safety and PK Study of CC-90003 in Relapsed/Refractory Solid Tumors
The CC-90003-ST -001 trial is a first-in-man, open-label study in subjects with locally-advanced or wide spread cancers to determine if CC-90003 (an oral medication) can be adequately tolerated with minimal side effects.
Checked against the public recordLast updated Nov 18, 2019 · Source: ClinicalTrials.gov
What this study is about
- Purpose
- Treatment
- Study type
- Interventional
- Phase
- Phase 1
- Sponsor
- Celgene
- Interventions being studied
- Drug: CC-90003
How this study is categorized
These labels come from structured fields and exact terms in the public record.
Who may be able to participate
Inclusion Criteria: 1. Eligible study subjects in Part 1 and Part 2 must be 18 years or older 2. Eligible study subjects must have histologic or cytologic confirmation of advanced, unresectable or metastatic solid tumors, and have at least one measurable lesion per Response Evaluation Criteria in Solid Tumors (RECIST) Version 1.1 3. Eligible study subjects must have Eastern Cooperative Oncology Group Performance Status (ECOG PS) of 0 or 1 4. Eligible study subjects must exhibit acceptable liver, bone marrow, renal and cardiac functions as assessed by laboratory tests, ECG and ECHO or MUGA scan. Exclusion Criteria: 1. Subjects with symptomatic or unstable CNS metastases 2. Subjects with a history of recent (within 28 days) systemic therapy for their underlying malignancy 3. Subjects who have had surgery/radiotherapy within 2 weeks prior to start of study
Important: This is the sponsor’s public criteria, not a determination of eligibility. The study team must review your individual situation.
U.S. locations
- Cedars Sinai Medical Center, Inflammatory Bowel Disease CenterLos Angeles, California
- Smilow Cancer CenterNew Haven, Connecticut
- Levine Cancer InstituteCharlotte, North Carolina
- Sarah Cannon Cancer CenterNashville, Tennessee
- Peter MacCallum Cancer CentreMelbourne
Source and freshness
Processed from ClinicalTrials.gov. Last public update: Nov 18, 2019. Always confirm current availability with the study team.